H. G. Boxenbaum, H. N. Posmanter, T. Macasieb et K. A. Geitner, « Pharmacokinetics of flunitrazepam following single- and multiple-dose oral administration to healthy human subjects », Journal of Pharmacokinetics and Biopharmaceutics, vol. 6, no 4, , p. 283–293 (ISSN0090-466X, PMID29954, DOI10.1007/BF01060092, lire en ligne, consulté le )
C. Drouet-Coassolo, A. Iliadis, P. Coassolo et M. Antoni, « Pharmacokinetics of flunitrazepam following single dose oral administration in liver disease patients compared with healthy volunteers », Fundamental & Clinical Pharmacology, vol. 4, no 6, , p. 643–651 (ISSN0767-3981, PMID2096104, DOI10.1111/j.1472-8206.1990.tb00044.x, lire en ligne, consulté le )
Tianze Cheng, Dominique Marie Wallace, Benjamin Ponteri et Mahir Tuli, « Valium without dependence? Individual GABAA receptor subtype contribution toward benzodiazepine addiction, tolerance, and therapeutic effects », Neuropsychiatric Disease and Treatment, vol. 14, , p. 1351–1361 (ISSN1176-6328, PMID29872302, PMCID5973310, DOI10.2147/NDT.S164307, lire en ligne, consulté le )
(en) Wolfgang Löscher et Michael A. Rogawski, « How theories evolved concerning the mechanism of action of barbiturates », Epilepsia, vol. 53, no s8, , p. 12–25 (ISSN1528-1167, DOI10.1111/epi.12025, lire en ligne, consulté le )
Allison Matthews, Kenneth C. Kirkby et Frances Martin, « The effects of single-dose lorazepam on memory and behavioural learning », Journal of Psychopharmacology (Oxford, England), vol. 16, no 4, , p. 345–354 (ISSN0269-8811, PMID12503834, DOI10.1177/026988110201600409, lire en ligne, consulté le )
L. Kangas, J. Kanto, V. Lehtinen et J. Salminen, « Long-term nitrazepam treatment in psychiatric out-patients with insomnia », Psychopharmacology, vol. 63, no 1, , p. 63–66 (ISSN0033-3158, PMID112623, DOI10.1007/BF00426923, lire en ligne, consulté le )
Andrew D. Krystal, Milton Erman, Gary K. Zammit et C. Soubrane, « Long-term efficacy and safety of zolpidem extended-release 12.5 mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia: a 6-month, randomized, double-blind, placebo-controlled, parallel-group, multicenter study », Sleep, vol. 31, no 1, , p. 79–90 (ISSN0161-8105, PMID18220081, PMCID2225552, DOI10.1093/sleep/31.1.79, lire en ligne, consulté le )
James K. Walsh, Andrew D. Krystal, David A. Amato et Robert Rubens, « Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations », Sleep, vol. 30, no 8, , p. 959–968 (ISSN0161-8105, PMID17702264, PMCID1978384, DOI10.1093/sleep/30.8.959, lire en ligne, consulté le )
M. Seppälä, J. Alihanka, J. J. Himberg et J. Kanto, « Midazolam and flunitrazepam: pharmacokinetics and effects on night time respiration and body movements in the elderly », International Journal of Clinical Pharmacology, Therapy, and Toxicology, vol. 31, no 4, , p. 170–176 (ISSN0174-4879, PMID8500918, lire en ligne, consulté le )
H. G. Boxenbaum, H. N. Posmanter, T. Macasieb et K. A. Geitner, « Pharmacokinetics of flunitrazepam following single- and multiple-dose oral administration to healthy human subjects », Journal of Pharmacokinetics and Biopharmaceutics, vol. 6, no 4, , p. 283–293 (ISSN0090-466X, PMID29954, DOI10.1007/BF01060092, lire en ligne, consulté le )
C. Drouet-Coassolo, A. Iliadis, P. Coassolo et M. Antoni, « Pharmacokinetics of flunitrazepam following single dose oral administration in liver disease patients compared with healthy volunteers », Fundamental & Clinical Pharmacology, vol. 4, no 6, , p. 643–651 (ISSN0767-3981, PMID2096104, DOI10.1111/j.1472-8206.1990.tb00044.x, lire en ligne, consulté le )
Tianze Cheng, Dominique Marie Wallace, Benjamin Ponteri et Mahir Tuli, « Valium without dependence? Individual GABAA receptor subtype contribution toward benzodiazepine addiction, tolerance, and therapeutic effects », Neuropsychiatric Disease and Treatment, vol. 14, , p. 1351–1361 (ISSN1176-6328, PMID29872302, PMCID5973310, DOI10.2147/NDT.S164307, lire en ligne, consulté le )
(en) Wolfgang Löscher et Michael A. Rogawski, « How theories evolved concerning the mechanism of action of barbiturates », Epilepsia, vol. 53, no s8, , p. 12–25 (ISSN1528-1167, DOI10.1111/epi.12025, lire en ligne, consulté le )
Allison Matthews, Kenneth C. Kirkby et Frances Martin, « The effects of single-dose lorazepam on memory and behavioural learning », Journal of Psychopharmacology (Oxford, England), vol. 16, no 4, , p. 345–354 (ISSN0269-8811, PMID12503834, DOI10.1177/026988110201600409, lire en ligne, consulté le )
L. Kangas, J. Kanto, V. Lehtinen et J. Salminen, « Long-term nitrazepam treatment in psychiatric out-patients with insomnia », Psychopharmacology, vol. 63, no 1, , p. 63–66 (ISSN0033-3158, PMID112623, DOI10.1007/BF00426923, lire en ligne, consulté le )
Andrew D. Krystal, Milton Erman, Gary K. Zammit et C. Soubrane, « Long-term efficacy and safety of zolpidem extended-release 12.5 mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia: a 6-month, randomized, double-blind, placebo-controlled, parallel-group, multicenter study », Sleep, vol. 31, no 1, , p. 79–90 (ISSN0161-8105, PMID18220081, PMCID2225552, DOI10.1093/sleep/31.1.79, lire en ligne, consulté le )
James K. Walsh, Andrew D. Krystal, David A. Amato et Robert Rubens, « Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations », Sleep, vol. 30, no 8, , p. 959–968 (ISSN0161-8105, PMID17702264, PMCID1978384, DOI10.1093/sleep/30.8.959, lire en ligne, consulté le )
M. Seppälä, J. Alihanka, J. J. Himberg et J. Kanto, « Midazolam and flunitrazepam: pharmacokinetics and effects on night time respiration and body movements in the elderly », International Journal of Clinical Pharmacology, Therapy, and Toxicology, vol. 31, no 4, , p. 170–176 (ISSN0174-4879, PMID8500918, lire en ligne, consulté le )
H. G. Boxenbaum, H. N. Posmanter, T. Macasieb et K. A. Geitner, « Pharmacokinetics of flunitrazepam following single- and multiple-dose oral administration to healthy human subjects », Journal of Pharmacokinetics and Biopharmaceutics, vol. 6, no 4, , p. 283–293 (ISSN0090-466X, PMID29954, DOI10.1007/BF01060092, lire en ligne, consulté le )
C. Drouet-Coassolo, A. Iliadis, P. Coassolo et M. Antoni, « Pharmacokinetics of flunitrazepam following single dose oral administration in liver disease patients compared with healthy volunteers », Fundamental & Clinical Pharmacology, vol. 4, no 6, , p. 643–651 (ISSN0767-3981, PMID2096104, DOI10.1111/j.1472-8206.1990.tb00044.x, lire en ligne, consulté le )
Tianze Cheng, Dominique Marie Wallace, Benjamin Ponteri et Mahir Tuli, « Valium without dependence? Individual GABAA receptor subtype contribution toward benzodiazepine addiction, tolerance, and therapeutic effects », Neuropsychiatric Disease and Treatment, vol. 14, , p. 1351–1361 (ISSN1176-6328, PMID29872302, PMCID5973310, DOI10.2147/NDT.S164307, lire en ligne, consulté le )
Allison Matthews, Kenneth C. Kirkby et Frances Martin, « The effects of single-dose lorazepam on memory and behavioural learning », Journal of Psychopharmacology (Oxford, England), vol. 16, no 4, , p. 345–354 (ISSN0269-8811, PMID12503834, DOI10.1177/026988110201600409, lire en ligne, consulté le )
L. Kangas, J. Kanto, V. Lehtinen et J. Salminen, « Long-term nitrazepam treatment in psychiatric out-patients with insomnia », Psychopharmacology, vol. 63, no 1, , p. 63–66 (ISSN0033-3158, PMID112623, DOI10.1007/BF00426923, lire en ligne, consulté le )
Andrew D. Krystal, Milton Erman, Gary K. Zammit et C. Soubrane, « Long-term efficacy and safety of zolpidem extended-release 12.5 mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia: a 6-month, randomized, double-blind, placebo-controlled, parallel-group, multicenter study », Sleep, vol. 31, no 1, , p. 79–90 (ISSN0161-8105, PMID18220081, PMCID2225552, DOI10.1093/sleep/31.1.79, lire en ligne, consulté le )
James K. Walsh, Andrew D. Krystal, David A. Amato et Robert Rubens, « Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations », Sleep, vol. 30, no 8, , p. 959–968 (ISSN0161-8105, PMID17702264, PMCID1978384, DOI10.1093/sleep/30.8.959, lire en ligne, consulté le )
M. Seppälä, J. Alihanka, J. J. Himberg et J. Kanto, « Midazolam and flunitrazepam: pharmacokinetics and effects on night time respiration and body movements in the elderly », International Journal of Clinical Pharmacology, Therapy, and Toxicology, vol. 31, no 4, , p. 170–176 (ISSN0174-4879, PMID8500918, lire en ligne, consulté le )
H. G. Boxenbaum, H. N. Posmanter, T. Macasieb et K. A. Geitner, « Pharmacokinetics of flunitrazepam following single- and multiple-dose oral administration to healthy human subjects », Journal of Pharmacokinetics and Biopharmaceutics, vol. 6, no 4, , p. 283–293 (ISSN0090-466X, PMID29954, DOI10.1007/BF01060092, lire en ligne, consulté le )
C. Drouet-Coassolo, A. Iliadis, P. Coassolo et M. Antoni, « Pharmacokinetics of flunitrazepam following single dose oral administration in liver disease patients compared with healthy volunteers », Fundamental & Clinical Pharmacology, vol. 4, no 6, , p. 643–651 (ISSN0767-3981, PMID2096104, DOI10.1111/j.1472-8206.1990.tb00044.x, lire en ligne, consulté le )
L. Kangas, J. Kanto, V. Lehtinen et J. Salminen, « Long-term nitrazepam treatment in psychiatric out-patients with insomnia », Psychopharmacology, vol. 63, no 1, , p. 63–66 (ISSN0033-3158, PMID112623, DOI10.1007/BF00426923, lire en ligne, consulté le )
(en) Wolfgang Löscher et Michael A. Rogawski, « How theories evolved concerning the mechanism of action of barbiturates », Epilepsia, vol. 53, no s8, , p. 12–25 (ISSN1528-1167, DOI10.1111/epi.12025, lire en ligne, consulté le )